Treatment of a Case of Pediatric Hypereosinophilic Syndrome with Anti-Interleukin-5 - 07/08/11
Doi : 10.1016/j.jpeds.2009.01.058
Sam Mehr, MBBS, BMedSci, FRCPA, FRACP a, b, Sylvan Rego, MBBS a, Alyson Kakakios, MBBS, FRACP a, Henry Kilham, MBBS, FRACP c, Andrew Kemp, MBBS, PhD, FRACP a, b
a Department of Allergy & Immunology, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
b Discipline of Pediatrics and Child Health, The Children’s Hospital at Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia
c Department of General Pediatrics, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
Abstract |
We report the use of anti-interleukin-5 (mepolizumab) during an 18-month period in a pediatric hypereosinophilic syndrome. Infusions every 3 months allowed better control of hypereosinophilic syndrome flares and maintained blood eosinopenia with significantly less steroid use compared with all other therapies (prednisolone alone, interferon alpha, or imatinib mesylate).
Le texte complet de cet article est disponible en PDF.Mots-clés : FIP1L1-PDGFRA, HES, IFN⍺, IL-5
Plan
| GlaxoSmithKline provided the supply of anti-IL-5 (mepomizulab). S.M. was partially supported by funds received from the Australian Allergy Foundation. The authors declare no conflicts of interest. |
© 2009
Mosby, Inc. Tous droits réservés.
Vol 155 - N° 2
P. 289-291 - août 2009 Retour au numéro
Article précédent
- 50 Years Ago in The Journal of Pediatrics : Indications and Contraindications for Surgery in Ventricular Septal Defect
- Craig R. Cohen
- Vascular Perfusion Abnormalities in Infants with Spinal Muscular Atrophy
- Alexandra prufer de Queiroz Campos Araujo, Mario Araujo, Kathryn J. Swoboda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?